You are here: All Products  > GenoImmune, a GBI Company, Completes Funding for NeoAntigen Cell Therapies

GenoImmune, a GBI Company, Completes Funding for NeoAntigen Cell Therapies

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.